Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology

Nina Movsesyan, Hayk Davtyan, Mikayel Mkrtichyan, Irina Petrushina, Tigran Tiraturyan, Ted Ross, Michael G. Agadjanyan, Anahit Ghochikyan, David H. Cribbs

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

It has been demonstrated that an active vaccination strategy with protein- or DNA-based epitope vaccines composed of the immunodominant self B cell epitope of amyloid-β42 (Aβ42) and a non-self T helper (Th) cell epitope is an immunotherapeutic approach to preventing or treating Alzheimer's disease (AD). As a DNA-based epitope vaccine, we used a plasmid encoding three copies of Aβ1-11 and Th cell epitope, PADRE (p3Aβ1-11-PADRE). We have previously reported that three copies of component of complement C3d (3C3d) acts as a molecular adjuvant significantly enhancing immune responses in wild-type mice of the H2b haplotype immunized with p3Aβ1-11-PADRE. Here, we tested the efficacy of p3Aβ1-11-PADRE and the same vaccine fused with 3C3d (p3Aβ1-11-PADRE-3C3d) in a transgenic (Tg) mouse model of AD (Tg2576) of the H2bxs immune haplotype. The overall responses to both vaccines were very weak in Tg2576 mice despite the fact that the 3C3d molecular adjuvant significantly enhanced the anti-Aβ response to 3Aβ1-11-PADRE. Importantly, generation of low antibody responses was associated with the strain of amyloid precursor protein Tg mice rather than with a molecular adjuvant, as a p3Aβ1-11-PADRE-3C3d vaccine induced significantly higher antibody production in another AD mouse model, 3xTg-AD of the H2b haplotype. Finally, this study demonstrated that low concentrations of antibodies generated by both DNA vaccines were not sufficient for the reduction of Aβ pathology in the brains of vaccinated Tg2576 animals, confirming previous reports from preclinical studies and the AN-1792 clinical trials, which concluded that the concentration of anti-Aβ antibodies may be essential for the reduction of AD pathology.

Original languageEnglish (US)
Pages (from-to)1569-1576
Number of pages8
JournalHuman Gene Therapy
Volume21
Issue number11
DOIs
StatePublished - Nov 1 2010

Fingerprint

DNA Vaccines
Epitopes
Anti-Idiotypic Antibodies
Alzheimer Disease
Vaccines
Pathology
Haplotypes
T-Lymphocyte Epitopes
Transgenic Mice
Antibody Formation
Complement C3d
B-Lymphocyte Epitopes
Amyloid beta-Protein Precursor
DNA
Amyloid
Vaccination
Plasmids
Clinical Trials
Antibodies
Brain

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology. / Movsesyan, Nina; Davtyan, Hayk; Mkrtichyan, Mikayel; Petrushina, Irina; Tiraturyan, Tigran; Ross, Ted; Agadjanyan, Michael G.; Ghochikyan, Anahit; Cribbs, David H.

In: Human Gene Therapy, Vol. 21, No. 11, 01.11.2010, p. 1569-1576.

Research output: Contribution to journalArticle

Movsesyan, N, Davtyan, H, Mkrtichyan, M, Petrushina, I, Tiraturyan, T, Ross, T, Agadjanyan, MG, Ghochikyan, A & Cribbs, DH 2010, 'Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology', Human Gene Therapy, vol. 21, no. 11, pp. 1569-1576. https://doi.org/10.1089/hum.2009.219
Movsesyan, Nina ; Davtyan, Hayk ; Mkrtichyan, Mikayel ; Petrushina, Irina ; Tiraturyan, Tigran ; Ross, Ted ; Agadjanyan, Michael G. ; Ghochikyan, Anahit ; Cribbs, David H. / Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology. In: Human Gene Therapy. 2010 ; Vol. 21, No. 11. pp. 1569-1576.
@article{535be3c3b78142229f7c4e7320a97d78,
title = "Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology",
abstract = "It has been demonstrated that an active vaccination strategy with protein- or DNA-based epitope vaccines composed of the immunodominant self B cell epitope of amyloid-β42 (Aβ42) and a non-self T helper (Th) cell epitope is an immunotherapeutic approach to preventing or treating Alzheimer's disease (AD). As a DNA-based epitope vaccine, we used a plasmid encoding three copies of Aβ1-11 and Th cell epitope, PADRE (p3Aβ1-11-PADRE). We have previously reported that three copies of component of complement C3d (3C3d) acts as a molecular adjuvant significantly enhancing immune responses in wild-type mice of the H2b haplotype immunized with p3Aβ1-11-PADRE. Here, we tested the efficacy of p3Aβ1-11-PADRE and the same vaccine fused with 3C3d (p3Aβ1-11-PADRE-3C3d) in a transgenic (Tg) mouse model of AD (Tg2576) of the H2bxs immune haplotype. The overall responses to both vaccines were very weak in Tg2576 mice despite the fact that the 3C3d molecular adjuvant significantly enhanced the anti-Aβ response to 3Aβ1-11-PADRE. Importantly, generation of low antibody responses was associated with the strain of amyloid precursor protein Tg mice rather than with a molecular adjuvant, as a p3Aβ1-11-PADRE-3C3d vaccine induced significantly higher antibody production in another AD mouse model, 3xTg-AD of the H2b haplotype. Finally, this study demonstrated that low concentrations of antibodies generated by both DNA vaccines were not sufficient for the reduction of Aβ pathology in the brains of vaccinated Tg2576 animals, confirming previous reports from preclinical studies and the AN-1792 clinical trials, which concluded that the concentration of anti-Aβ antibodies may be essential for the reduction of AD pathology.",
author = "Nina Movsesyan and Hayk Davtyan and Mikayel Mkrtichyan and Irina Petrushina and Tigran Tiraturyan and Ted Ross and Agadjanyan, {Michael G.} and Anahit Ghochikyan and Cribbs, {David H.}",
year = "2010",
month = "11",
day = "1",
doi = "10.1089/hum.2009.219",
language = "English (US)",
volume = "21",
pages = "1569--1576",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology

AU - Movsesyan, Nina

AU - Davtyan, Hayk

AU - Mkrtichyan, Mikayel

AU - Petrushina, Irina

AU - Tiraturyan, Tigran

AU - Ross, Ted

AU - Agadjanyan, Michael G.

AU - Ghochikyan, Anahit

AU - Cribbs, David H.

PY - 2010/11/1

Y1 - 2010/11/1

N2 - It has been demonstrated that an active vaccination strategy with protein- or DNA-based epitope vaccines composed of the immunodominant self B cell epitope of amyloid-β42 (Aβ42) and a non-self T helper (Th) cell epitope is an immunotherapeutic approach to preventing or treating Alzheimer's disease (AD). As a DNA-based epitope vaccine, we used a plasmid encoding three copies of Aβ1-11 and Th cell epitope, PADRE (p3Aβ1-11-PADRE). We have previously reported that three copies of component of complement C3d (3C3d) acts as a molecular adjuvant significantly enhancing immune responses in wild-type mice of the H2b haplotype immunized with p3Aβ1-11-PADRE. Here, we tested the efficacy of p3Aβ1-11-PADRE and the same vaccine fused with 3C3d (p3Aβ1-11-PADRE-3C3d) in a transgenic (Tg) mouse model of AD (Tg2576) of the H2bxs immune haplotype. The overall responses to both vaccines were very weak in Tg2576 mice despite the fact that the 3C3d molecular adjuvant significantly enhanced the anti-Aβ response to 3Aβ1-11-PADRE. Importantly, generation of low antibody responses was associated with the strain of amyloid precursor protein Tg mice rather than with a molecular adjuvant, as a p3Aβ1-11-PADRE-3C3d vaccine induced significantly higher antibody production in another AD mouse model, 3xTg-AD of the H2b haplotype. Finally, this study demonstrated that low concentrations of antibodies generated by both DNA vaccines were not sufficient for the reduction of Aβ pathology in the brains of vaccinated Tg2576 animals, confirming previous reports from preclinical studies and the AN-1792 clinical trials, which concluded that the concentration of anti-Aβ antibodies may be essential for the reduction of AD pathology.

AB - It has been demonstrated that an active vaccination strategy with protein- or DNA-based epitope vaccines composed of the immunodominant self B cell epitope of amyloid-β42 (Aβ42) and a non-self T helper (Th) cell epitope is an immunotherapeutic approach to preventing or treating Alzheimer's disease (AD). As a DNA-based epitope vaccine, we used a plasmid encoding three copies of Aβ1-11 and Th cell epitope, PADRE (p3Aβ1-11-PADRE). We have previously reported that three copies of component of complement C3d (3C3d) acts as a molecular adjuvant significantly enhancing immune responses in wild-type mice of the H2b haplotype immunized with p3Aβ1-11-PADRE. Here, we tested the efficacy of p3Aβ1-11-PADRE and the same vaccine fused with 3C3d (p3Aβ1-11-PADRE-3C3d) in a transgenic (Tg) mouse model of AD (Tg2576) of the H2bxs immune haplotype. The overall responses to both vaccines were very weak in Tg2576 mice despite the fact that the 3C3d molecular adjuvant significantly enhanced the anti-Aβ response to 3Aβ1-11-PADRE. Importantly, generation of low antibody responses was associated with the strain of amyloid precursor protein Tg mice rather than with a molecular adjuvant, as a p3Aβ1-11-PADRE-3C3d vaccine induced significantly higher antibody production in another AD mouse model, 3xTg-AD of the H2b haplotype. Finally, this study demonstrated that low concentrations of antibodies generated by both DNA vaccines were not sufficient for the reduction of Aβ pathology in the brains of vaccinated Tg2576 animals, confirming previous reports from preclinical studies and the AN-1792 clinical trials, which concluded that the concentration of anti-Aβ antibodies may be essential for the reduction of AD pathology.

UR - http://www.scopus.com/inward/record.url?scp=78649380771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649380771&partnerID=8YFLogxK

U2 - 10.1089/hum.2009.219

DO - 10.1089/hum.2009.219

M3 - Article

VL - 21

SP - 1569

EP - 1576

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 11

ER -